Abogen
Founded Year
2003Stage
Series C - II | AliveTotal Raised
$1.134BValuation
$0000Last Raised
$300M | 2 yrs agoMissing: Abogen's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Abogen's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Abogen
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Abogen is included in 4 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,214 items
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Cancer
3,605 items
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Abogen Patents
Abogen has filed 21 patents.
The 3 most popular patent topics include:
- Analytical chemistry
- Chromatography
- Elastomers
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/24/2016 | 3/7/2023 | Piperazines, Fluoroarenes, Atypical antipsychotics, Piperidines, Acetylcholinesterase inhibitors | Grant |
Application Date | 10/24/2016 |
|---|---|
Grant Date | 3/7/2023 |
Title | |
Related Topics | Piperazines, Fluoroarenes, Atypical antipsychotics, Piperidines, Acetylcholinesterase inhibitors |
Status | Grant |
Latest Abogen News
Jun 24, 2022
publication date: Jun 24, 2022 Shanghai Genor Biopharma has teamed up with Suzhou Abogen Biosciences to develop novel mRNA drugs for oncology indications, merging its biological antibody development platform with Abogen’s mRNA platform. Genor has expertise in identifying bi-specific/multi-specific antibodies for immunoncology. Abogen, which was already an mRNA company before COVID, adapted its technology to develop a mRNA vaccine for the pandemic. Based on the global interest in COVID vaccines, it raised $700 million in a C round one year ago to conduct Phase III trials. Financial details of the agreement were not disclosed. More details.... Stock Symbol: (HK: 6998)
Abogen Frequently Asked Questions (FAQ)
When was Abogen founded?
Abogen was founded in 2003.
Where is Abogen's headquarters?
Abogen's headquarters is located at B2-610, Biomedicine Industrial Park, No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou.
What is Abogen's latest funding round?
Abogen's latest funding round is Series C - II.
How much did Abogen raise?
Abogen raised a total of $1.134B.
Who are the investors of Abogen?
Investors of Abogen include 5Y Capital, DNE Capital, SoftBank , Chimera Investments, New Frontier and 37 more.
Who are Abogen's competitors?
Competitors of Abogen include NeoCura.
Compare Abogen to Competitors
NeoCura is a supplier of molecular diagnostic products, covering the entire clinical cycle from the early detection and diagnosis of tumors to precise medical guidance and treatment evaluation.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.